Literature DB >> 25454639

Vascular comorbidities in the onset and progression of multiple sclerosis.

Prudence Tettey1, Steve Simpson1, Bruce V Taylor1, Ingrid A F van der Mei2.   

Abstract

Vascular comorbidities are common in the general population and are associated with adverse health outcomes. In people with multiple sclerosis (MS), an increasing amount of evidence suggests that vascular comorbidities are also common, but an association with MS risk and disability has not been conclusively established. This review aims to critically examine published data on the relationship between vascular comorbidities (including vascular risk factors) and MS. The evidence suggests an increased risk of MS in people with a high BMI during childhood or adolescence but not adulthood. People with established MS appear to have a slightly increased risk of cardiovascular disease and a greater proportion of people with MS die from cardiovascular disease, which has important implications for clinicians trying to identify risk factors for cardiovascular disease and reviewing treatment options. In relation to whether vascular comorbidities influence MS clinical disability or other aspects of the disease course, the key finding was that having type-2-diabetes, hypertension, dyslipidaemia or peripheral vascular disease at any point in the disease course may be associated with a greater progression in disability. Additionally, a negative effect of high cholesterol and triglycerides and a positive effect of higher HDL (high density lipoprotein) levels on acute inflammatory activity were observed on magnetic resonance imaging. The results of the published clinical trials of statins as an intervention in MS were however conflicting and care needs to be taken when treating people with MS with statins. Taken together, the literature seems to indicate a potential association of vascular comorbidities with MS risk and disability, but the number of prospective studies was sparse, thus precluding ascription of causality. We therefore recommend that future studies of the frequency and effects of vascular comorbidities on MS risk and disability should be prospective and objective where relevant.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Comorbidities; Disability; Lipids; Multiple sclerosis; Obesity; Statins

Mesh:

Substances:

Year:  2014        PMID: 25454639     DOI: 10.1016/j.jns.2014.10.020

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  26 in total

1.  Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

Authors:  Kelly Fellows; Tomas Uher; Richard W Browne; Bianca Weinstock-Guttman; Dana Horakova; Helena Posova; Manuela Vaneckova; Zdenek Seidl; Jan Krasensky; Michaela Tyblova; Eva Havrdova; Robert Zivadinov; Murali Ramanathan
Journal:  J Lipid Res       Date:  2015-08-04       Impact factor: 5.922

2.  Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

Authors:  Tomas Uher; Kelly Fellows; Dana Horakova; Robert Zivadinov; Manuela Vaneckova; Lukas Sobisek; Michaela Tyblova; Zdenek Seidl; Jan Krasensky; Niels Bergsland; Bianca Weinstock-Guttman; Eva Havrdova; Murali Ramanathan
Journal:  J Lipid Res       Date:  2016-12-06       Impact factor: 5.922

3.  Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.

Authors:  Shreya Mukhopadhyay; Kelly Fellows; Richard W Browne; Prachi Khare; Sandhya Krishnan Radhakrishnan; Jesper Hagemeier; Bianca Weinstock-Guttman; Robert Zivadinov; Murali Ramanathan
Journal:  Mult Scler       Date:  2016-09-28       Impact factor: 6.312

4.  Effects of physical comorbidities on disability progression in multiple sclerosis.

Authors:  Tingting Zhang; Helen Tremlett; Feng Zhu; Elaine Kingwell; John D Fisk; Virender Bhan; Trudy Campbell; Karen Stadnyk; Robert Carruthers; Christina Wolfson; Sharon Warren; Ruth Ann Marrie
Journal:  Neurology       Date:  2018-01-03       Impact factor: 9.910

5.  Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS.

Authors:  Amber Salter; Tuula Tyry; Guoqiao Wang; Robert J Fox; Gary Cutter; Ruth Ann Marrie
Journal:  Neurol Clin Pract       Date:  2016-10

6.  Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis.

Authors:  R Zivadinov; B Raj; M Ramanathan; B Teter; J Durfee; M G Dwyer; N Bergsland; C Kolb; D Hojnacki; R H Benedict; B Weinstock-Guttman
Journal:  AJNR Am J Neuroradiol       Date:  2016-02-18       Impact factor: 3.825

7.  Cardiovascular Dysfunction in Multiple Sclerosis.

Authors:  Raluca Ileana Mincu; Lucia Stefania Magda; Maria Florescu; Andreea Velcea; Sorina Mihaila; Diana Mihalcea; Bogdan O Popescu; Adela Chiru; Cristina Tiu; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Bucur)       Date:  2015-09

8.  Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study.

Authors:  Kelly Fellows Maxwell; Sonia Bhattacharya; Mary Lou Bodziak; Dejan Jakimovski; Jesper Hagemeier; Richard W Browne; Bianca Weinstock-Guttman; Robert Zivadinov; Murali Ramanathan
Journal:  J Lipid Res       Date:  2019-05-13       Impact factor: 5.922

9.  Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.

Authors:  Angeliki G Filippatou; Jeffrey Lambe; Elias S Sotirchos; Kathryn C Fitzgerald; Andrew Aston; Olwen C Murphy; Nicole Pellegrini; Nicholas Fioravante; Hunter Risher; Esther Ogbuokiri; Ohemaa Kwakyi; Brandon Toliver; Simidele Davis; Nicholas Luciano; Ciprian Crainiceanu; Jerry L Prince; Ellen M Mowry; Peter A Calabresi; Shiv Saidha
Journal:  Mult Scler       Date:  2020-04-16       Impact factor: 6.312

10.  Fractional anisotropy of white matter, disability and blood iron parameters in multiple sclerosis.

Authors:  Estelle Herbert; Penelope Engel-Hills; Coenraad Hattingh; Jean-Paul Fouche; Martin Kidd; Christine Lochner; Maritha J Kotze; Susan J van Rensburg
Journal:  Metab Brain Dis       Date:  2018-02-02       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.